[go: up one dir, main page]

FR2872704B1 - Pluritherapie contre le cancer - Google Patents

Pluritherapie contre le cancer

Info

Publication number
FR2872704B1
FR2872704B1 FR0407752A FR0407752A FR2872704B1 FR 2872704 B1 FR2872704 B1 FR 2872704B1 FR 0407752 A FR0407752 A FR 0407752A FR 0407752 A FR0407752 A FR 0407752A FR 2872704 B1 FR2872704 B1 FR 2872704B1
Authority
FR
France
Prior art keywords
pluritherapy
against cancer
cancer
pluritherapy against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0407752A
Other languages
English (en)
Other versions
FR2872704A1 (fr
Inventor
Laurent Schwartz
Maurice Israel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to FR0407752A priority Critical patent/FR2872704B1/fr
Priority to US11/572,068 priority patent/US20070280918A1/en
Priority to EP05790826A priority patent/EP1771164A1/fr
Priority to PCT/FR2005/001797 priority patent/WO2006016062A1/fr
Priority to JP2007520862A priority patent/JP2008505960A/ja
Publication of FR2872704A1 publication Critical patent/FR2872704A1/fr
Application granted granted Critical
Publication of FR2872704B1 publication Critical patent/FR2872704B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR0407752A 2004-07-12 2004-07-12 Pluritherapie contre le cancer Expired - Fee Related FR2872704B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR0407752A FR2872704B1 (fr) 2004-07-12 2004-07-12 Pluritherapie contre le cancer
US11/572,068 US20070280918A1 (en) 2004-07-12 2005-07-12 Multitherapy Against Cancer
EP05790826A EP1771164A1 (fr) 2004-07-12 2005-07-12 Pluritherapie contre le cancer
PCT/FR2005/001797 WO2006016062A1 (fr) 2004-07-12 2005-07-12 Pluritherapie contre le cancer
JP2007520862A JP2008505960A (ja) 2004-07-12 2005-07-12 多剤癌治療

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0407752A FR2872704B1 (fr) 2004-07-12 2004-07-12 Pluritherapie contre le cancer

Publications (2)

Publication Number Publication Date
FR2872704A1 FR2872704A1 (fr) 2006-01-13
FR2872704B1 true FR2872704B1 (fr) 2007-11-02

Family

ID=34950695

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0407752A Expired - Fee Related FR2872704B1 (fr) 2004-07-12 2004-07-12 Pluritherapie contre le cancer

Country Status (5)

Country Link
US (1) US20070280918A1 (fr)
EP (1) EP1771164A1 (fr)
JP (1) JP2008505960A (fr)
FR (1) FR2872704B1 (fr)
WO (1) WO2006016062A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2477604A1 (fr) 2002-03-13 2003-09-25 Signum Biosciences, Inc. Modulation de la methylation de proteines et du phosphate des phosphoproteines
EP1843734A4 (fr) 2005-02-03 2008-09-10 Signum Biosciences Inc Compositions et procedes pour l'amelioration de la fonction cognitive
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
WO2007092414A2 (fr) * 2006-02-06 2007-08-16 Lixte Biotechnology Holdings, Inc. Utilisation de phosphatase pour traiter des tumeurs surexprimant n-cor
US20090233905A1 (en) * 2006-04-05 2009-09-17 Gregory Peter Burke Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer
US20090018142A9 (en) * 2006-05-02 2009-01-15 Zhengping Zhuang Use of phosphatases to treat tumors overexpressing N-CoR
AU2008214299B2 (en) 2007-02-06 2014-01-09 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
JP5279235B2 (ja) * 2007-11-05 2013-09-04 国立大学法人 岡山大学 抗癌剤耐性癌において抗癌剤増強作用を有する癌細胞死誘導剤
WO2009132051A1 (fr) 2008-04-21 2009-10-29 Signum Biosciences, Inc. Composés, compositions et procédés pour préparer ceux-ci
WO2010147612A1 (fr) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Procédés de modulation de la régulation cellulaire par inhibition de p53
EP2344453B1 (fr) 2008-10-09 2016-12-28 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Activateurs de la pyruvate kinase humaine
CN102448951B (zh) 2009-04-06 2017-05-10 安吉奥斯医药品有限公司 丙酮酸激酶m2调节剂、治疗组合物和相关使用方法
DK2427441T3 (en) 2009-05-04 2017-03-20 Agios Pharmaceuticals Inc PKM2 Activators for use in the treatment of cancer
DK2448581T3 (en) 2009-06-29 2017-03-13 Agios Pharmaceuticals Inc Therapeutic compositions and methods for their applications
LT2448582T (lt) * 2009-06-29 2017-07-10 Agios Pharmaceuticals, Inc. Chinolin-8-sulfonamido dariniai, turintys priešvėžinį aktyvumą
JP2013525438A (ja) 2010-04-29 2013-06-20 アメリカ合衆国 ヒトピルビン酸キナーゼ活性剤
EP2651898B1 (fr) 2010-12-17 2015-12-09 Agios Pharmaceuticals, Inc. Nouveaux dérivés de n-(4-(azétidine- 1 - carbonyl) phényl)-(hétéro-) arylsulfonamide en tant que modulateurs de la pyruvate kinase m2 (pmk2)
CA2822432C (fr) 2010-12-21 2019-09-24 Agios Pharmaceuticals, Inc. Activateurs bicycliques de pkm2
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
HUE065700T2 (hu) 2011-05-03 2024-06-28 Agios Pharmaceuticals Inc Piruvát-kináz aktivátorok terápiában történõ alkalmazásra
KR101370108B1 (ko) 2012-03-28 2014-03-20 가톨릭대학교 산학협력단 위암 진단용 마커로서 ｈｄａｃ2의 용도
FR3001889B1 (fr) * 2013-02-11 2021-02-12 Expanscience Lab Utilisation d'une composition comprenant un perseose d'avocat dans la protection des cellules souches epidermiques .
BR112015025852A2 (pt) 2013-04-09 2017-07-25 Lixte Biotechnology Inc as formulações de oxabicicloheptanos e oxabicicloheptenos
WO2015103480A1 (fr) 2014-01-02 2015-07-09 Massachusetts Eye & Ear Infirmary Traitement de la néovascularisation oculaire
MX2017008097A (es) * 2014-12-17 2018-01-09 Verrica Pharmaceuticals Inc Sintesis comercialmente viable de cantaridina y derivados bioactivos de cantaridina.
LT3307271T (lt) 2015-06-11 2023-10-25 Agios Pharmaceuticals, Inc. Piruvatkinazės aktyvatorių panaudojimo būdai
IL290857B2 (en) 2016-12-08 2023-03-01 Lixte Biotechnology Inc Oxabicycloheptanes for immune response modulation
IL314274A (en) 2017-06-06 2024-09-01 Verrica Pharmaceuticals Inc Treatment of cutaneous disorders
USD900312S1 (en) 2017-06-15 2020-10-27 Verrica Pharmaceuticals, Inc. Applicator
EP3692044B1 (fr) 2017-10-04 2024-01-24 Verrica Pharmaceuticals, Inc. Synthèse de cantharidine
US20220275368A1 (en) 2019-08-12 2022-09-01 Interna Technologies B.V. New treatments involving mirna-193a
CA3167367A1 (fr) 2020-02-28 2021-09-02 Sanaz YAHYANEJAD Miarn-193a pour favoriser la mort cellulaire immunogene

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69229910T2 (de) * 1991-10-07 2000-04-20 Otsuka Pharmaceutical Factory, Inc. Enterale zubereitungen zur krebstherapie
WO1998011122A1 (fr) * 1996-09-13 1998-03-19 Nutramax Laboratories, Inc. Composition nutritive a base de selenium et de s-adenosylmethionine
US20020002146A1 (en) * 2000-02-11 2002-01-03 Halevie-Goldman Brian D. Compositions and methods for the production of S-adenosylmethionine within the body
CA2477604A1 (fr) * 2002-03-13 2003-09-25 Signum Biosciences, Inc. Modulation de la methylation de proteines et du phosphate des phosphoproteines
DE20207569U1 (de) * 2002-05-14 2002-12-05 Kyberg Pharma Vertriebs-GmbH & Co. KG, 82041 Oberhaching Diätetische und pharmazeutische Zusammensetzungen
CN100361599C (zh) * 2002-10-23 2008-01-16 克尔塞根控股有限公司 抗氧化组合物
US6821536B2 (en) * 2002-11-22 2004-11-23 Quercegen Holdings Llc Antioxidative compositions

Also Published As

Publication number Publication date
EP1771164A1 (fr) 2007-04-11
FR2872704A1 (fr) 2006-01-13
JP2008505960A (ja) 2008-02-28
WO2006016062A1 (fr) 2006-02-16
US20070280918A1 (en) 2007-12-06

Similar Documents

Publication Publication Date Title
NL301242I2 (nl) ublituximab
FR2872704B1 (fr) Pluritherapie contre le cancer
CY2019034I1 (el) 4-φαινυλαμινο-κιναζολιν-6-υλ-αμιδια
FI20040892L (fi) Pala-antenni
DE112005001624A5 (de) Brillengestell
DE602006013094D1 (de) Krebsmittel
ATE520680T1 (de) Hiv-hemmende 5-heterocyclylpyrimidine
ATE392425T1 (de) Thiazolyl-dihydro-indazole
ATE459633T1 (de) Makrolide
DE502005004843D1 (de) Einspritzventil
EP1894575A4 (fr) Agent thérapeutique contre le cancer
EP1908459A4 (fr) Composition prévenant le cancer
DE502005004842D1 (de) Wischblatt
DE112005000809A5 (de) Wankstabilisierungseinrichtung
DE502004012213D1 (de) Flachdichtung
EP1789064A4 (fr) Traitement anticancéreux amélioré
DE602005012919D1 (de) Brillenendstück
DE502005000310D1 (de) Koaxialsteckverbinder
DE502005002602D1 (de) Fahrzeugtemperiersystem
DE502005000513D1 (de) Mikrowellengerät
DE502005004695D1 (de) Sicherheitsfangseil
AT500198B1 (de) Ladewagen
DE112005000794T5 (de) Urethanspritzpistolenanordnung
ATE389633T1 (de) Omega-phenyloctanamide
EP1595546A4 (fr) Remede contre le cancer

Legal Events

Date Code Title Description
TP Transmission of property
ST Notification of lapse

Effective date: 20100331